

Two Factorial Randomized Clinical Trial comparing dose and timing of estrogen supplementation on the prevention of atherosclerotic cardiovascular disease in post menopausal women

Student ID: 997900158

March 11, 2013

Abstract

This two factorial multicenter randomized clinical trial was conducted on a convenience sample of peri-menopausal women presenting to North American Kaiser Permanente hospitals in 2001-2002. The women were given differing levels of estrogen supplementation both before and after the onset of menopause, and the level of carotid intima-media thickness measured to assess progression of atherosclerotic cardiovascular disease, as well as cases of clinical atherosclerotic cardiovascular disease recorded. The women were followed up for 8 years (until 2010) results revealed early supplementation of low dose estrogen is as protective as high dose, but with less side effects.

1 Introduction

Atherosclerotic cardiovascular disease is the buildup of fatty deposits and white blood cells in arterial walls which results in hardening of the arteries which can cause thromboembolism and myocardial infarction. It is an important cause of cardiovascular disease in people but prevalence rates are difficult to determine due to its subclinical signs until a clinical atherosclerotic cardiovascular disease event. Even though there has been an overall decline in the death rate due to cardiovascular disease in the United States over several decades, the rate of decline is less for women and especially african-american women [1]. In 1994, Cardiovascular disease killed a half

million women and accounted for over 40% of all deaths in women, more than all forms of cancer combined[2]. While men are more commonly affected by cardiovascular disease, risk increases rapidly in women as they age, doubles every decade after age 55[3]. This age related increase in risk is in part due to the onset of menopause (the absence of a menstrual cycle in the previous 12 months) which occurs at an average age of 51 but can range between 45 and 55 years [4]. It has been shown that reduced circulating oestradiol during menopause increases atherogenic lipids and reduces carotid blood flow, causing increased incidence of atherosclerotic cardiovascular disease [5]. Supplemental oestrogen has been used for some time to treat symptoms of menopause and its associated increase in atherosclerotic cardiovascular disease risk, however serious side effects (higher risk of breast cancer, increased blood clots and endometrial cancer) have been documented [4]. Recent research has also investigated the cardiovascular protection associated with menopausal hormonal therapy and concluded no overall benefit of supplemental estrogen overall, and a possible interaction between time of therapy initiation and protection provided [6, 7]. Since the initial research questioning the efficacy of menopausal hormonal therapy was completed, there have been numerous innovations in the form and dose of estrogen delivery have occurred, and it is hypothesised that these new forms/dosing regimens may provide improved protection.

This two-by-two factorial randomized clinical trial is designed to assess the effects of initiating estradiol supplementation at different doses and different times around the onset of menopause on the risk of atherosclerotic cardiovascular disease. The study Hypothesis is that initiating estrogen therapy before the onset of menopause is protective of atherosclerotic cardiovascular disease, and that a reduced dose of estrogen provides the same protection with reduced side effects.

2 Methods

The study population was a convenience sample drawn from women presenting to Kaiser Permanente health clinics between 2000-01-01 and 2000-12-31, aged between 40 and 50 that were undergoing signs of peri-menopause (last cycle less than 12 months ago, but no regular monthly cycle). Kaiser Permanente is a managed care consortium based in northern California. It has almost 15,000 physicians operating in 650 facilities spread over 9 states, and serves nearly 9 million members [8]. On identifying a possible study subject, a full physical examination and medical history was taken, and where possible validated with a central database of historical medical records maintained by Kaiser Permanente. During this physical examination BP, BMI, race, and age were measured, and lifestyle factors such as smoking and physical activity levels recorded. Blood was also collected during this initial examination and levels of lipoproteins measured.

Any woman with a previous hysterectomy, had taken estrogen supplements in the past, or had experienced any prolonged angina was disqualified from the study as hysterectomy causes instant menopause at any age, and angina may be a sign of preexisting heart conditions. The results of blood screening was assessed and any women with high levels of Low density lipoproteins was excluded. The thickness of carotid artery intima-media was recorded by ultrasound and any individual with stenosis greater than 75% was excluded, as this is considered a cutoff for clinically significant disease [9]. This initial measurement of carotid intima-media thickness also provided a baseline against which future measurements could be compared to to assess disease progression. Women whose medical history differed significantly from that recorded in Kaiser Permanente records was also excluded, as this may indicate future compliance and recall issues.

Sample size requirements were calculated using epi-info with a subclinical atherosclerotic cardiovascular disease rate of 25%, as shown in figure 1.

Interim analysis were completed at bi-yearly intervals by an independent data and safety monitoring committee, and the decision to proceed based on participant safety (no increased rates of side effects or atherosclerotic

cardiovascular disease) and the perceived benefit of continuing with study. O'Brien-Flemming spending strategy was used to generate stopping boundaries for each planned analysis.

Two factorial design was chosen to allow simultaneous comparison of dose and timing effects, and the use of a very large sample size allowed the assessment of interactions at sufficient power. The two dose levels chosen were 0.625mg and 0.3mg of conjugated equine estrogens, delivered per os (hence denoted high and low respectively). 0.625 mg SID PO is the standard therapy currently in use, the lower dose of 0.3mg has been suggested as a way to maximise benefit (menopause symptoms, CVD, osteoporosis), while minimising harmful side effects (cancer risk, blood clots) associated with estrogen. The two timing levels chosen were initiation of therapy during peri menopause (early intervention), or initiation 3 years after menopause (late intervention). The use of a two factorial design resulted in 4 study groups, as described in [figure 1](#).

Patients were randomised using a centralised allocation procedure, with both patient and physician blinded to allocation method. There was no blocking or stratification of study participants performed. After eligibility was established, the physician sent an auto generated email containing patient information to a server maintained in the researchers office at Kaiser Permanente's headquarters in Oakland, California. This computer used a schedule of random numbers generated from open radio frequency atmospheric noise [10] and study participants were allocated to one of the four groups based on this number. The allocation, general patient details, and source clinic and timestamp of the allocation request were recorded and compared to doctor's own records of assignment to ensure accuracy. The result of this allocation was returned to the physician in an email with a number 1-4 and the appropriate treatment initiated.

Following assignment, all patients received a 6 month supply of pills, regardless of group assignment. This pill pack was in nondescript packaging, with only a number label, and was renewed every 6 months by mail from Kaiser Permanente headquarters. Even after assignment, the allocation sequence and allocation itself was concealed from study participant and

physician. Those that were assigned late delivery of either dose were initially given sugar pills that had same appearance, taste, and smell as the real estrogen pills. 3 years after menopause was determined to have taken place (more than 12 months amenorrhoea) these study participants had their next 6 monthly supply of pills converted to estrogen, at a dose depending on their assignment. Again there was no way to tell the difference between pills having different doses.

Patients were followed for 9 years (2001-01-01 - 2009-12-31) and had annual checkups with their Kaiser Permanente physician during the study period. During this examination, a standard examination and history was performed, as well specific questions relating to the onset of menopause, symptoms experienced during the year, and any incidence of angina or clinical cardiovascular disease. The incidence of side effects of estrogen therapy monitored included cancer (breast, colon, endometrial), and clotting events (Deep Vein Thrombosis, Ischaemic stroke) was also asked and recorded. All women had their responses checked against actual medical history, improving accuracy of data and minimising recall bias.

To assess the progression of subclinical atherosclerotic cardiovascular disease, women had a carotid ultrasound to measure carotid artery intima-media thickness. The thickness of carotid artery intima-media was recorded and compared to previous measurements to assess disease progression. This intervention was well tolerated as women were presenting to their health professional for an annual checkup anyway, and the Carotid ultrasound is quick and non-invasive. In addition, the quality of these measurements were maintained by using a trained ultrasonographer at each of the Kaiser Permanente facilities. Before the beginning of enrollment, these ultrasonographers were trained at a central location on a standard protocol for taking measurements, and the inter-observer agreement assessed by each ultrasonographer completing an examination of the same 5 test subjects.

All patients were thoroughly briefed on the study design and interventions, and signed informed consent and liability release forms.

2.1 Statistical Evaluation

The primary study endpoint was progression of subclinical atherosclerotic cardiovascular disease defined as an increase in carotid inter-media thickness of more than 0.0035mm per year diagnosed on carotid ultrasound. A second study endpoint was clinical atherosclerotic cardiovascular disease, which signs included stroke, congestive heart disease, and death due to cardiac causes.

Kaplan-Meier survival curves for overall survival were compared by log-rank test, and the unadjusted HR (and 95% CI) was calculated using a Cox regression analysis. As a secondary analysis, potential covariates (race, age, smoking, physical activity levels) were included in the Cox regression model to generate an adjusted HR for overall survival.

All analysis was completed on an intention to treat basis, and all statistical analysis were completed in R [11] on data that had a random hashing algorithm performed before analysis, ensuring blinding of statisticians.

3 Results

43,426 women were initially enrolled in this study, with 42,236 assigned to a treatment group and 38,234 completing and were analysed in the study. The number of people allocated to each group and the number missing from each group can be seen in [Study flow](#)

Baseline characteristics of study participant can be seen in [Table 1](#).

Table 3 (no data required) shows the incidence of increased carotid inter-media thickness in all groups, and also adjusted Hazard ratios associated with included covariates. As can be seen, women who took the low dose and started during perimenopause had a lower risk of developing atherosclerotic cardiovascular disease, while. Subgroup analysis was performed on African American women, and smoking women. African-American women have a higher incidence of atherosclerotic cardiovascular disease than others, and our data reflected this, but the reduced risk of atherosclerotic cardiovascular disease with low dose early start estrogen was the same for African American women as the whole population. Women who smoke are also at higher inci-

dence of atherosclerotic cardiovascular disease, but once again our findings held for smokers and non smokers alike.

The incidence of side effects that can be caused by estrogen is shown in [Table 2](#), Comparison rates in post menopausal women not undergoing menopausal hormonal therapy are shown for comparison. As can be seen from Table 2, there is no increased risk of side effects associated with menopausal hormonal therapy.

The compliance rate among study participants was assessed by measuring estrogen levels in blood of a sample (n=100) of participants receiving estrogen at least 2 years following the onset of menopause. Compliance was found to be good, at 93%, and no adjustment was made for those found to be non compliant.

The rates of diagnosis on each ultrasonographer were compared to ensure inter-observer agreement. As each ultrasonographer completed many measurements, each individual observer distribution was compared to the average distribution of all observers, to determine if any one observer was over or under measuring carotid inter-media thickness. The interobserver correlation was above 90% and no single observer consistently over or under measured carotid inter-media thickness.

4 Discussion

4.1 Strengths and Limitations

Data quality was a strength of this study. Cross validating the patients oral medical histories with the actual recorded histories from the Kaiser Permanente central databases ensures accuracy and reduces recall bias. This improved the accuracy of measurement of secondary outcome, clinical atherosclerotic cardiovascular disease events. Study group allocation was entirely random and repeatable, and the comparison of allocation and actual treatment records allowed analysis to be undertaken on an accurate intention to treat basis. The effectiveness of this random allocation procedure can be seen in the comparability of groups in [Table 2](#) and shows the study has good inter-

nal validity. Primary outcome results were improved by the use of trained ultrasonographers who had been assessed pre trial (see above)

The triple blinding methods used in this study were also a strength, with study participants, consulting physicians, and statisticians all unaware of which group participants/data were assigned to. There was no need to assess the efficacy of blinding as any unmasking could only occur from physical changes in the participant, over which we had no control.

A potential limitation of this study was the selection of study participants from Kaiser Permanente hospitals. Rates of insurance are correlated with Socio economic status and Education level, both factors that are also associated with use of menopausal hormonal therapy. There may be some relationship between lifestyle factors/SES and progression of atherosclerotic cardiovascular disease, and our attempt to control for these factors (correcting for smoking and activity levels) may be insufficient. The use of a convenience sample from Kaiser Permanente external validity may be limited, however it is likely that Kaiser Permanente clientele represents a good sample of middle and upper class women hence findings are valid across this population.

Another potential limitation is the loss of blinding to study participants based on the effects of treatment. Some women experience bleeding when taking an estrogen supplement, and this would remove blinding.

The use of carotid inter-media thickness measurements to diagnose significant atherosclerotic cardiovascular disease may be inappropriate as it has been shown the presence of 'vulnerable plaques' vs a single carotid wall thickness measurement is more predictive of a clinical atherosclerotic cardiovascular disease event [9].

5 Conclusion

This study demonstrated a benefit from low dose e2 therapy started early in peri-menopause in protecting against subclinical and clinical atherosclerotic cardiovascular disease. Side effect rates in this study reflected those reported elsewhere, however recent work has shown alternative agents may

have reduced side effect rates. The use of early delivery of alternative estrogen preparations and delivery routes is one area of research where further investigation is warranted.

6 Figures




Figure 1: Flow Diagram showing study participant allocation

		Number				
Characteristic		Group 1	Group 2	Group 3	Group 4	
		low:early	low:late	high:early	high:late	
Demographic	age, median	51.30	50.90	51.20	50.98	
	%smoke	21%	23%	20%	22%	
	% > 3hr physical activity/wk	15%	16%	14%	15%	
	% african american	12%	14%	13%	12%	
Medical	BP, systolic mean	103.00	105.00	101.00	107.00	
	BMI	24.00	25.00	27.00	24.00	
	% high LDL	8%	7%	6%	7%	
	months since last cycle, mean	18.00	17.00	15.00	19.00	
total		10552	10563	10559	10562	42236

Figure 2: Characteristics of study participants.

		Number				Gen.pop
Side Effect		Group 1 low:early	Group 2 low:late	Group 3 high:early	Group 4 high:late	
Cancer	Breast	10	12	17	15	16
	Colon	22	26	18	21	24
	Endometrial	36	32	38	33	34
Clotting	Deep Vein Thrombosis	27	29	31	26	28
	Ischaemic stroke	52	54	48	49	50
	Congestive heart disease	68	72	70	71	69
	Death due to cardiac causes	106	108	110	107	105
total		10552	10563	10559	10562	42236

Figure 3: Incidence of Side effects in study groups

C:\PROGRA~1\EPI_INFO\STATCALC.EXE

EpiInfo Version 6StatcalcNovember 1993

Unmatched Cohort and Cross-Sectional Studies (Exposed and Nonexposed)
Sample Sizes for 4.00 % Disease in Unexposed Group

Conf.	Power	Unex:Exp	Disease in Exposed	Risk Ratio	Odds Ratio	Sample Size		Total
95.00 %	80.00 %	1:1	7.69 %	1.92	2.00	Unexp.	Exposed	
95.00 %	"	"				686	686	1,372
90.00 %	"	"				551	551	1,102
95.00 %	"	"				686	686	1,372
99.00 %	"	"				995	995	1,990
99.90 %	"	"				1,431	1,431	2,862
95.00 %	80.00 %	"				686	686	1,372
"	90.00 %	"				900	900	1,800
"	95.00 %	"				1,100	1,100	2,200
"	99.00 %	"				1,532	1,532	3,064
"	80.00 %	4:1				1,588	397	1,985
"	"	3:1				1,290	430	1,720
"	"	2:1				988	494	1,482
"	"	1:2				532	1,064	1,596
"	"	1:3				480	1,439	1,919
"	"	1:4				453	1,813	2,266

Change values for
inputs as desired,
then press F4 to
recalculate.

F1-HelpF5-PrintF6-Open FileF10-Done

Figure 4: Sample size function and calculation output from R. Calculations agrees with Epi Info when continuity correction was applied.

References

- [1] L. Mosca, J. E. Manson, S. E. Sutherland, R. D. Langer, T. Manolio, and E. Barrett-Connor. Cardiovascular Disease in Women : A Statement for Healthcare Professionals From the American Heart Association. *Circulation*, 96(7):2468–2482, October 1997.
- [2] AHA. *1997 Heart and Stroke Facts: Statistical Update*. American Heart Association, Dallas, TX, 1997.
- [3] T Gordon and WB Kannel. Menopause and coronary heart disease. The Framingham Study. *Annals of internal . . .*, 1978.
- [4] Gold, Kass, and Stuckey. MPM406 ass 3 description. pages 1–3, 2012.
- [5] Howard N Hodis and Wendy J Mack. Atherosclerosis Imaging Methods : Assessing Cardiovascular Disease and Evaluating the Role of Estrogen in the Prevention of Atherosclerosis. *American journal of cardiology*, 9149(02):19–27, 2002.
- [6] GL Anderson and MC Limacher. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. *JAMA: the journal of . . .*, 2004.
- [7] Ross L Prentice, Joann E Manson, Robert D Langer, Garnet L Anderson, Mary Pettinger, Rebecca D Jackson, Karen C Johnson, Lewis H Kuller, Dorothy S Lane, Jean Wactawski-Wende, Robert Brzyski, Matthew Allison, Judith Ockene, Gloria Sarto, and Jacques E Rossouw. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. *American journal of epidemiology*, 170(1):12–23, July 2009.
- [8] Chris Rauber. Kaiser to cut 1,200 jobs in Northern California - Sacramento Business Journal, 2009.
- [9] Attilio Maseri and Valentin Fuster. Is there a vulnerable plaque? *Circulation*, 107(16):2068–71, April 2003.

- [10] Dirk Eddelbuettel. *random: True random numbers using random.org*, 2009.
- [11] R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria, 2012.